Additional Study Information: The purpose of this research study is to determine whether rosuvastatin is safe and can help people living with cirrhosis lead longer, healthier lives. The study drug, rosuvastatin, is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration (FDA). Participants will first enter a 4-week period receiving rosuvastatin to assess tolerability. They will then be randomly assigned to take either rosuvastatin or placebo (inactive substance) for 96 weeks. This is a double-blind study, so the study doctors and participants will not know whether or not they are receiving rosuvastatin or placebo. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).